Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_2
4
80%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Completed2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

completed240%
terminated240%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

NCT02836470
terminatedphase_3

A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

NCT05470387
withdrawnphase_2

LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia

NCT04390217
completedphase_2

Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

NCT05056935
terminatedphase_2

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

NCT02317549

Clinical Trials (5)

Showing 5 of 5 trials
NCT02836470Phase 2

A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

Completed
NCT05470387Phase 3

A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

Terminated
NCT04390217Phase 2

LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia

Withdrawn
NCT05056935Phase 2

Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

Completed
NCT02317549Phase 2

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5